Raxatrigine

Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.[1][2] In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[4][non-primary source needed]
Raxatrigine
Raxatrigine
Raxatrigine.svg
Clinical data
Routes of
administration
Oral
ATC code None
Identifiers
CAS Number 934240-30-9
934240-35-4 (mesylate)
PubChem (CID) 16046068
ChemSpider 13174481
Chemical and physical data
Formula C18H19FN2O2
Molar mass 314.354063 g/mol
3D model (Jmol) Interactive image

Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.[1][2] In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[4][non-primary source needed]

See also

References

  1. ^ a b Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals". 
  2. ^ a b Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0. 
  3. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923. 
  4. ^ MarketWatch (2014). "Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study". 


منبع: ویکی پدیا

پربازدیدترین

Image

The New Republic

The New Republic is a liberal American magazine of commentary ... ویکی پدیا
Image

گلکسی Active Neo رسما معرفی شد

گلکسی Active Neo از سامسونگ رسما معرفی شد؛ میان رده ای ارزان ا ... جی اس ام آرنا
Image

سنجش تأثیر آموزش‌ شهروندی بر توانمندسازی زنان

بررسی رابطۀ آموزش‌های ارائه‌شده بر سطح توانمندی زنان هدف اصلی ... خبرگزاری فارس

جدیدترین ها

پربازدیدها در این موضوع

Image

تصاویری از پل دایره ای در اروگوئه

ساخت این پل به شکل دایره باعث کاهش سرعت رانندگان شده است تا آن ... پاندا
Image

خطوط اسرار آمیز نازکا +تصاویر

خطوط نازکا مجموعه‌ای از خطوطی است که در صحرای نازکا،در یک دشت ... ویکی پدیا
No image

آشنایی با خواص دارچین

صدف کوه کن:دارچین از گذشته به عنوان چاشنی، دارو و ادویه در تما ... همشهری آنلاین

سایر مطالب

بالا
Powered by TayaCMS